Liraglutide is a glucagon-like peptide-1 (GLP-1) agonist reducing activation of brain areas associated with appetite and reward, and is used in the treatment of type 2 diabetes and obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.